{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:50:06Z","timestamp":1773694206329,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373123"],"award-info":[{"award-number":["82373123"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072736"],"award-info":[{"award-number":["82072736"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gastrointestinal Surgery"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.gassur.2025.102265","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:03:54Z","timestamp":1760911434000},"page":"102265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of combined pathological response in primary tumor and lymph nodes after neoadjuvant chemoimmunotherapy for locally advanced gastric cancer"],"prefix":"10.1016","volume":"30","author":[{"given":"Xiong","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7723-6121","authenticated-orcid":false,"given":"Kaixiong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.gassur.2025.102265_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.gassur.2025.102265_bib2","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","article-title":"Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (Classic): 5-year follow-up of an open-label, randomised phase 3 trial","volume":"15","author":"Noh","year":"2014","journal-title":"Lancet Oncol"},{"issue":"33","key":"10.1016\/j.gassur.2025.102265_bib3","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","article-title":"Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer","volume":"29","author":"Sasako","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2025.102265_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.gassur.2025.102265_bib5","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10184","key":"10.1016\/j.gassur.2025.102265_bib6","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.gassur.2025.102265_bib7","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1007\/s00262-023-03566-5","article-title":"Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer","volume":"72","author":"Li","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.gassur.2025.102265_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.959295","article-title":"Neoadjuvant tislelizumab and tegafur\/gimeracil\/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: early results of a phase 2, single-arm trial","volume":"12","author":"Yin","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.gassur.2025.102265_bib9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41591-023-02721-w","article-title":"Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial","volume":"30","author":"Yuan","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.gassur.2025.102265_bib10","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s10120-023-01431-z","article-title":"SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score-matched analysis","volume":"26","author":"Huang","year":"2023","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.gassur.2025.102265_bib11","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1186\/s12885-023-11508-8","article-title":"Concurrent clinical and pathological response predicts favorable prognosis of patients with gastric cancer after neoadjuvant therapy: a real-world study","volume":"23","author":"Sun","year":"2023","journal-title":"BMC Cancer"},{"issue":"19","key":"10.1016\/j.gassur.2025.102265_bib12","doi-asserted-by":"crossref","first-page":"19633","DOI":"10.1002\/cam4.6597","article-title":"Tumor regression grade combined with post-therapy lymph node status: a novel independent prognostic factor for patients treated with neoadjuvant therapy followed by surgery in locally advanced gastroesophageal junction and gastric carcinoma","volume":"12","author":"Yin","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.gassur.2025.102265_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107401","article-title":"Evaluation of combined pathological responses in primary tumor and lymph nodes following neoadjuvant chemoimmunotherapy in non-small cell lung cancer","volume":"186","author":"Huang","year":"2023","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.gassur.2025.102265_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40164-023-00401-6","article-title":"\u201cMajor pathologic response\u201d in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy","volume":"12","author":"Deng","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.gassur.2025.102265_bib15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejca.2023.03.008","article-title":"Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma","volume":"186","author":"Wang","year":"2023","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.gassur.2025.102265_bib16","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.gassur.2025.102265_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.gassur.2025.102265_bib18","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/SLA.0b013e318216f449","article-title":"Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases","volume":"253","author":"Becker","year":"2011","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.gassur.2025.102265_bib19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41591-023-02758-x","article-title":"Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.gassur.2025.102265_bib20","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jamaoncol.2023.4423","article-title":"Chemotherapy and immune checkpoint blockade for gastric and gastroesophageal junction adenocarcinoma","volume":"9","author":"Manji","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2025.102265_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41467-023-44309-5","article-title":"Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial","volume":"15","author":"Lin","year":"2024","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.gassur.2025.102265_bib22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2025.102265_bib23","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1038\/s41467-021-25188-0","article-title":"Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer","volume":"12","author":"Cascone","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.gassur.2025.102265_bib24","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1007\/s12094-023-03130-8","article-title":"Comparison of the predictive value of pathological response at primary tumor and lymph node status after neoadjuvant chemotherapy in locally advanced gastric cancer","volume":"25","author":"Su","year":"2023","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"10.1016\/j.gassur.2025.102265_bib25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.21037\/tlcr.2020.03.03","article-title":"Heterogeneity of neoantigen landscape between primary lesions and their matched metastases in lung cancer","volume":"9","author":"Jiang","year":"2020","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"10.1016\/j.gassur.2025.102265_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002230","article-title":"Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer","volume":"9","author":"Moutafi","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.gassur.2025.102265_bib27","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2017.07.025","article-title":"Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient","volume":"170","author":"Jim\u00e9nez-S\u00e1nchez","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.gassur.2025.102265_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.820566","article-title":"Case report: durable complete response after combined immunotherapy following resection of primary tumor in a gallbladder cancer patient with distant metastatic lymph nodes of favorable immune-microenvironment","volume":"13","author":"Yi","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.gassur.2025.102265_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005160","article-title":"Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis","volume":"10","author":"Zhai","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.gassur.2025.102265_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12957-021-02157-x","article-title":"Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer","volume":"19","author":"Jiang","year":"2021","journal-title":"World J Surg Oncol"},{"issue":"5","key":"10.1016\/j.gassur.2025.102265_bib31","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jtcvs.2020.08.108","article-title":"Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy","volume":"162","author":"Corsini","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"10.1016\/j.gassur.2025.102265_bib32","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1245\/s10434-023-14690-y","article-title":"Multimodal therapy versus primary surgery for gastric and gastroesophageal junction diffuse type carcinoma, with a focus on signet ring cell carcinoma: a nationwide study","volume":"31","author":"Gertsen","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2025.102265_bib33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12957-022-02699-8","article-title":"Comparison between signet-ring cell carcinoma and non-signet-ring cell carcinoma of the stomach: clinicopathological parameters, epidemiological data, outcome, and prognosis-a cohort study of 123 patients from a non-endemic country","volume":"20","author":"Zaafouri","year":"2022","journal-title":"World J Surg Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2025.102265_bib34","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1038\/s41467-023-38426-4","article-title":"Single-cell analysis of gastric signet ring cell carcinoma reveals cytological and immune microenvironment features","volume":"14","author":"Zhao","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.gassur.2025.102265_bib35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2023.03.008","article-title":"Single-cell profiling of tumor immune microenvironment reveals immune irresponsiveness in gastric signet-ring cell carcinoma","volume":"165","author":"Chen","year":"2023","journal-title":"Gastroenterology"}],"container-title":["Journal of Gastrointestinal Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X25003245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X25003245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T19:59:25Z","timestamp":1773691165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091255X25003245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1091255X25003245"],"URL":"https:\/\/doi.org\/10.1016\/j.gassur.2025.102265","relation":{},"ISSN":["1091-255X"],"issn-type":[{"value":"1091-255X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic value of combined pathological response in primary tumor and lymph nodes after neoadjuvant chemoimmunotherapy for locally advanced gastric cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Gastrointestinal Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gassur.2025.102265","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Society for Surgery of the Alimentary Tract. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102265"}}